VanEck Associates’s Ligand Pharmaceuticals LGND Stock Holding History

VanEck Associates’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-404	Closed	-$26K	–	898
2016 Q4	$26K	Buy	404 +199	+97%	+$12.6K	﹤0.01%	860
2016 Q3	$13K	Sell	205 -109	-35%	-$8K	﹤0.01%	854
2016 Q2	$23K	Buy	314 +30	+11%	+$2.23K	﹤0.01%	827
2016 Q1	$19K	Buy	+284	New	+$17.3K	﹤0.01%	805

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

VanEck Associates's LGND Position: Q1 2017 in Review

VanEck Associates sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 404 shares — an estimated $26K sold.

VanEck Associates first reported a position in LGND in Q1 2016 and held it in 4 quarters. The position peaked at $26K in Q4 2016. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

VanEck Associates reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
VanEck Associates sold 404 Ligand Pharmaceuticals shares in Q1 2017, an estimated $26K.
VanEck Associates first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 4 quarters.
VanEck Associates's Ligand Pharmaceuticals position peaked at $26K in Q4 2016.
256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on VanEck Associates's 13F filing for Q1 2017, filed 11 May 2017.